Symptom Burden and Health Related Quality of Life of Cancer Patients With Concurrent Heart Failure

The investigators will conduct a symptom assessment at study enrollment on cancer participants with a concurrent diagnosis of HF (HFrEF and HFpEF) using the MD Anderson Symptom Inventory- Heart Failure (MDASI-HF) and PROMIS Instruments (Fatigue, Dyspnea, and Sleep Disturbance).

The investigators will also describe and compare the health-related quality of life using the European Organization for Research and Training Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) and the measure of Quality of Life Short Form-12 (SF-12).

Inclusion criteria

• Age 18 years and older
• Individuals with a concurrent solid tumor cancer diagnosis
• Not receiving active cancer treatment except for those on maintenance (i.e., Selective ER modulators (SERMs)[Tamoxifen], Aromatase inhibitors (Anastrozole, Letrozole, Exemestane), Ovarian suppression therapy (GnRH Agonists [Leuprolide], Androgen deprivation therapy for prostate cancer
• Completed cancer treatment at least 3 months and up to 3 years before study enrollment.

Therapy

• Able to read, speak and consent in English
• Ability to understand and the willingness to sign a written informed consent document
• Diagnosis of heart failure, confirmed by echocardiogram, MUGA, or cardiac catheterization
• Internet access via smart phone, tablet, a computer, or another device with the capacity to 1) download the Fitbit App and 2) complete electronic study assessments via REDCap.

Exclusion criteria

• Participants undergoing active cancer treatment.
• Inability to provide consent in the medical record, such as cognitively impaired individuals.